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Summary The cardiotoxicity of 5-fluorouracil (FU) was attributed to impurities present in the injected vials.
One of these impurities was identified as fluoroacetaldehyde which is metabolised by isolated perfused rabbit
hearts into fluoroacetate (FAC), a highly cardiotoxic compound. FAC was also detected in the urine of
patients treated with FU. These impurities were found to be degradation products of FU that are formed in
the basic medium employed to dissolve this compound. To avoid chemical degradation of this antineoplastic
drug, the solution of FU that will be injected should be prepared immediately before use.
5-fluorouracil (FU) is widely used alone or in combined
protocols in the treatment of various malignancies including
gastrointestinal, breast and head and neck cancer. Common
clinical adverse reactions include myelosuppression, diarrhea
and mucositis. The cardiotoxicity of FU which was first
reported in 1975 (Dent & McColl, 1975) was thought to be
an infrequent, albeit severe, toxic side-effect. The incidence of
FU cardiotoxicity was reported to be 1.6% in a retrospective
study of 1,083 patients receiving FU in various protocols
(Labianca et al., 1982). However, over the last decade, a
number of retrospective or anecdotal reports have pointed to
a higher incidence of FU-related complications in patients
receiving high doses of FU. Incidences of 6.5% (de Forni et
al., 1990), and 7.9% (Gradishar et al., 1990) have been
recently reported. In an analysis of 38 cases of FU cardiotox-
icity in the literature, Collins and Weiden (1987) found that
26% of the patients who experienced cardiac events during
FU chemotherapy either died or were severely disabled. Few
studies have been designed to assess prospectively the risk of
FU cardiotoxicity. In 76 patients given cisplatin in combina-
tion with a continuous i.v. infusion of FU with regular
clinical and ECG examination, Eskilsson et al. (1988) observ-
ed adverse cardiac events (chest pain, arrythmia, ECG
changes) in 14 patients (18%). By continuous ECG monitor-
ing in 25 patients receiving a similar protocol, Rezkalla et al.
(1989) observed ischemic ECG changes in 68% of patients
during treatment vs 24% prior to FU administration. In 281
patients receiving a continuous i.v. infusion of high doses of
FU, cardiac events occurred in 26 patients (9.3%) and the
lethality rate was 2.5% (de Forni et al., 1991).
Various hypotheses including ischemia secondary to coron-
ary artery spasm, interaction of FU with the coagulation
system, immunoallergic phenomena, direct toxicity of FU on
the myocardium have been proposed to explain the cardio-
toxicity of this drug (Freeman & Costanza, 1988; Ensley et
al., 1989; Gradishar & Vokes, 1990). However, the precise
biochemical mechanism underlying this toxic side-effect still
remains unknown even if the metabolic pathways of FU have
now been largely elucidated (Heidelberger et al., 1983). The
cytotoxic activity of this drug stems from the anabolic path-
way that leads to fluoronucleosides (FNUCs) then fluoro-
nucleotides (FNUCt). The degradative pathway of FU
biotransformation is called the catabolic pathway and mainly
leads to a-fluoro-p-alanine (FBAL), an a-fluoro-13-amino-acid
which closely resembles the natural P-amino-acid, 0-alanine.
P-alanine is converted into acetate which enters the Krebs
cycle and undergoes a metabolic conversion to citrate. By
analogy with the natural substrate, it has been suggested
but never demonstrated that FBAL might be transformed
into fluoroacetate (FAC) (Philips et al., 1959; Koenig &
Patel, 1970; Matsubara et al., 1980). FAC is known to be a
highly cardiotoxic and neurotoxic poison. Indeed, it also
enters the Krebs cycle, is then transformed into fluorocitrate
(FC) which inhibits citrate metabolism resulting in accumula-
tion of intracellular citrate (Pattison & Peters, 1966) (Figure
1).
Having at our disposal a powerful method for studying the
metabolism of fluorinated drugs, especially fluoropyrimidines
(Malet-Martino et al., 1990), we explored the possibility of a
direct toxic effect of FU or one of its metabolites on the
mycocardium using fluorine-19 nuclear magnetic resonance
('9F NMR) and the isolated perfused rabbbit heart (IPRH)
model. We also report in this paper the results of the '9F
NMR analysis of biofluids from patients treated with FU.
We demonstrate that a degradation compound of FU, result-
ing from the storage of this drug in alkaline conditions and
found in the injected vials, is responsible for the cardiotox-
icity of this antineoplastic drug since it is metabolised into
FAC.
Materials and methods
Materials
Commercial FU Roche vials from France (50 mg FU ml-' of
an aqueous solution buffered with Tris, pH = 8.5), Germany
(25 mg FU ml-' of an aqueous NaOH solution, pH = 8.5),
Great Britain (25 mg FU ml-I of an aqueous NaOH solu-
tion, pH = 8.5), USA (50 mg FU ml- of an aqueous NaOH
solution, pH = 9.2) and a commercial US generic from Solo-
Pak Laboratories (50 mg FU ml-' of an aqueous NaOH
solution, pH = 9.1) were used. The same batch of FU vials
was used throughout a series of experiments on IPRH (FU
Roche from France, B034S, expiration date 8/1992; from
Germany 10651, expiration date 30/6/1992; from USA, 1052-
10, expiration date 6/1/1992; FU SoloPak, 900835, expiration
date 2/1992). FU powder was from Sigma Chemical Co. (St.
Louis, Mo., USA) and from Hoffmann-La Roche Labora-
tories (Basel, Switzerland). FBAL was provided by Tokyo
Kasei Chemicals (Tokyo, Japan). FAC sodium salt, FC
baryum salt, Tris and 2-fluoroethanol were from Sigma
Chemical Co., and pyridinium chlorochromate from Aldrich
(Strasbourg, France). The test-combination for the enzymatic
assay of citrate (Cat No. 139076) was from Boehringer
(Mannheim, Germany).
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Figure 1 Metabolism ofP-alanine and catabolic pathway of FU.
Animals
Male rabbits (Oryctolagus cuniculus, 2-2.5 kg, 3-4 months)
maintained on a standard diet were used throughout.
Heart perfusion procedure
Rabbits were killed by cervical dislocation and bled. The
hearts were then quickly excised and arrested by immersion
in ice-cold Tyrode perfusion buffer. They were mounted on a
polypropylene cannula and perfused at 37°C in a recircu-
lating Langendorff mode; the pressure head was maintained
at 75 cm of water. The Tyrode perfusion buffer (300 ml) was
equilibrated with 95% 02/5% CO2 for at least 30 min before
use giving a pH of 7.4 ± 0.1 at 37°C, and had the following
composition mM: NaCl, 136,9; KCI, 2.68; CaC12, 1.8; MgC92,
1.05; NaHCO3, 11.9; NaH2PO4, 0.42; and glucose, 8.8. After
perfusion with Tyrode buffer for 30 min, the compounds to
be tested were added and the experiments were continued
until ventricular contractions ceased or for a further 4 h.
Heart rate and coronary flow rate were monitored during the
experiments. At the end of the experiment, the perfusate was
immediately frozen, lyophilised to dryness and stored at
-80°C until analysis. The heart was rinsed with 100 ml
Tyrode buffer and immediately immersed in liquid nitrogen.
Preparation ofheart extracts
The frozen tissue was minced and sequentially extracted with
cold and hot 7% (w/v) perchloric acid (PCA) by using the
method of Wain and Staatz (1973). The acid-soluble (AS)
and acid-insoluble (AI) fractions were lyophilised to dryness
and stored at - 80°C until analysis.
Patients
Thirty-three urine samples were taken from 15 patients
treated by continuous i.v. infusion of FU (600 to 1,000mg
m-2 for 4 or 5 consecutive days) alone or in combination
with folinic acid, mitomycin C or cisplatin (Table I). None of
the patients previously received anthracyclines. Six patients
had cardiac manifestations, nine had not. Only punctual
samples taken at day 2 or 3 of the treatment were anlaysed
for three patients without cardiotoxic symptoms (patients G,
H, K), and for the six patients who experienced cardiac
events (patients B, D, L, M, N, 0) since the treatment was
discontinued immediately after the onset of cardiotoxic
symptoms. For six patients without cardiotoxic symptoms
(patients A, C, E, F, I, J), urinary metabolites of FU ex-
creted over 24 h were quantitated during the first 3 or 4 days
of treatment. In order to eliminate errors in volume estima-
tions and since, for each patient, the excretion of FU cata-
bolites (cx-fluoro-p-ureidopropionic acid (FUPA) + FBAL) is
constant over 24 h during a continuous perfusion of FU, the
ratio FAC excreted over 24 h/FU catabolites excreted over
24 h was determined for each 24 h urine sample.
Urine samples from four control patients not receiving FU
were also analysed. Only a small amount of fluoride ion (F-)
was detected (3.7 10-1 M ± 1.8 1O-5 M).
To decrease the time of the '9F NMR analysis, urine
samples (10-200ml) were lyophilised to dryness. We verified
that the amount of FAC detected in crude urine was identical
to that determined in the same urine sample after lyophilisa-
tion taking the factor of concentration due to lyophilisation
into account.
Three plasma samples were analysed without being lyophi-
lised, extracted or derivatised.
Preparation ofsamplesfor '9FNMR analysis
The lyophilised materials (perfusates, AS and AI fractions,
urine samples) were solubilised in distilled water and the
solution was transferred to a NMR tube containing a coaxial
capillary tube filled with a solution of sodium parafluoro-
benzoate in D20 doped with the relaxation agent, chromium
(III) acetylacetonate. This solution, previously calibrated,
served as an external standard for quantification. For the
quantification of FU vials, about 2 mg of chromium (III)
acetylacetonate were added before transferring the solution
to the NMR tube.
'9F NMR analysis
'9F NMR spectra were recorded using a Bruker WB-AM 300
spectrometer with or without proton decoupling. The magne-
tic field was shimmed from the 'H NMR resonance of water.
The '9F NMR recording conditions were as follows: probe
temperature, 25°C; sweep width, 41,667 Hz; 32,768 data
points zero-filled to 65,536; pulse width, 7 gss (i.e. flip angle
-45°C); pulse interval, 1.4s or 3.4 s for quantification of
lysophilised materials or vials respectively; number of scans,
10,000-40,000; line broadening caused by exponential multi-
plication, 1-5 Hz.
The chemical shifts (6) were relative to the resonance peak
of the external reference CF3COOH (5% w/v aqueous solu-
tion). The variations in the observed 6 of some compounds
(0.3-1.5 ppm) are due to differences in pH and ionic strengths
of the samples analysed. The '9F NMR signals were attri-
buted to the classical FU metabolites according to literature
data (Malet-Martino & Martino, 1991), and by spiking with
authentic standards. The signals of FAC, fluoroacetaldehyde
(Facet), its condensation product with Tris (Facet-Tris) were
unambiguously assigned by adding the authentic compounds
and recording the '9F NMR spectra with and without proton
decoupling.
The concentrations of the fluorinated metabolites were
measured by comparing the expanded areas of their respec-
tive NMR signals with that of sodium parafluorobenzoate.
The areas were determined by weighing the cut out peaks.
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We checked that the quantification offluorinated metabolites
was not affected by the recording conditions used since a
repetition time of 10 s did not modify the intensities of the
signals.
'0
"I-
1-1
'0 '0-
_0' 10
_ ^
___'
en _ t
'0
'0
el-
'0
'0
'0
'0
'0'
en
e _4
'0
'10
'0
.-I
'0
'0
_ en cri en
'0'0'0'0_0'0
e- _~ll
1+1 + II +
> O.--> >- >> >
U c
000
0 o C>oo
CDo
CCC 0 CW CU C C CUCUCUCUCUCU
0 00 ;Pb 0 0 0 0 0 00 00 0
CU
0 0 ,~~~~~C ,m 0
Cd 0'0'0 '00 '00'
0CU'0 - oo- - 0 ' 0 ~0'0'm0' UCU c; > CU 00o 0 U UCUUUUU =14U 0 U QU U zuzz
It O t 00 It 0 00 0 0 e C WI ur W) 1% WI r en WI tn £1 'IC i
cn
U
CU
U
CU
0_
U 0t
.U
CU
Co
01
Uq
._U
cU
CU
'0
CU
CU
CU
0
CU
0
CU
0
CU
CU
0
C._8
CU
0 '0
'icU
- C Y,C.
._U
Determination ofintramyocardial citrate
The assay was carried out on the heart AS fractions using a
reagent containing citrate lyase (Citric acid Kit, Boehringer).
The amount of citrate was determined by following the
decrease of NADH absorbance at 340 nm.
Preparation of'purified' FU
Two ml of 70% PCA were added to three vials of FU (Tris)
Roche. The resulting pH was 2.8. The precipitate of FU was
recovered by centrifugation (Omin, 1,000g, 4°C) and wash-
ed with H20. The '9F NMR spectrum of a solution of the
powder obtained was devoid of signals from fluorinated
impurities. This powder was thus called 'purified' FU.
Synthesis ofFacet and its condensationproduct with Tris
(Facet-Tris = oxazolidine 2)
Fluoroethanol was treated with an equimolar amount of
pyridinium chlorochromate in dichloromethane for 2 h at
25°C (Tecle & Casida, 1989). The reaction mixture was then
extracted twice with H20. A saturated solution of Pb(NO3)2
was added to the aqueous phase leading to the precipitation
of lead chromate. The precipitate was centrifuged off
(10min, 1,000g, 4°C). The supernatant was adjusted to
pH;8 with 5 M KOH. A 30 molar excess of Tris with
respect to Facet was then added. The solution was lyo-
philised to dryness and the lyophilisate extracted with dichlo-
romethane. The organic phase containing Facet-Tris was
recovered and dichloromethane evaporated. The FAB posi-
tive mass spectral data showed the MH+ ion at m/z 166. '9F
NMR (H20) 6 (PPm) - 159.7 (td, 2JHF = 46.8 Hz, 3JHF =
18.9 HZ). 'H NMR (D20) 6 (PPm) CH22' (AB part of an
ABXY system) H2'A 4.55, H2'B 4.48 (3JH2'A-H2 = 2.4Hz,
3JH2'B-H2 = 3.5 Hz, 2JH2'A-H2'B = 10.7 Hz, 2JH2 A-F = 2JH2'B-F
46.8 HZ); CH25 (AB quartet) 3.60, 3.55 (J = 11.7 Hz);
CH20H 3.61 (s); CH20H (AB quartet) 3.72, 3.69 (J = 8.5 Hz);
the signal of residual H20 in D20 hides the signal of H2. 13C
NMR (H20) 6 (ppm) C2 91.8 (d, 2JCF = 19.7 Hz); C2 84.6 (d, IJCF= 169.2 Hz); C5 72.0; C4 69.0; C4, C4 65.1, 65.0.
Adjusting the solution of Facet-Tris to pH-5 with HCI
leads to Facet which is present in this solvent as Facet
hydrate 1. '9F NMR (H20) 6 (ppm) - 155.2 (td, 2JHF =
46.5 Hz, TJHF = 9.8 Hz). 'H NMR (D20) 6 (ppm) CH2 4.29
(dd, 2JHF = 46.5 HZ, 3JHH = 4.6 Hz); CH 5.19 (td, 3JHF =
9.8 Hz, 3JHH = 4.5 Hz). 13C NMR (H20) 6 (ppm) CH 90.4 (d,
2JCF = 22.7 Hz); CH2 87.3 (d, IJCF = 168.3 Hz).
Extraction ofFacet-Trisfrom FU (Tris) Roche vials
The contents of two vials were treated with 70% PCA in
order to precipitate FU. After centrifugation (10 min,
1,000g, 4°C), the supernatant was neutralised with 5 M
KOH. The KCI04 precipitate was removed by centrifugation
(Omin, 1,000g, 4°C) and the supernatant was lyophilised to
dryness. Dichloromethane was added to the residue and the
suspension was stirred for 30min at 25°C. After filtration,
the organic phase was recovered and dichloromethane evap-
orated. The spectroscopic characteristics of the compound
obtained were identical to those described for compound 2.
Acidification of a solution of the extracted compound in H20
led to compound 1, the spectroscopic characteristics ofwhich
were identical to those described above.
Statistics
All results were expressed as means ± s.d. Statistical signi-
ficance was determined by use of the Student's t-test. A P
value of <0.05 was considered statistically significant.
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Results
Isolatedperfused hearts treated with FU (Tris) Roche vials
To gain more understanding of the mechanism of FU cardio-
toxicity, we treated isolated perfused hearts from rabbits, a
species that is especially sensitive to the cardiotoxic effects of
FU (Suzuki et al., 1977), with FU Roche (vials of 0.25 g FU
in 5 ml aqueous solution buffered with Tris) at five doses
ranging from 15 to 180 mg FU kg-' b.w. (Table II). The time
before ventricular arrest decreased with increase in the
injected dose (P<0.05 for all the doses vs all the doses
except for doses 25 mg kg' vs 45 mg kg', 45 mg kg' vs
90mg kg-' and 90mg kg-' vs 180mg kg-'). Intracellular cit-
rate levels rose 20-60 fold with respect to the control
(P<0.0005 for all the five doses tested vs control). We
verified that Tris itself had no effect on intramyocardial
citrate level (P>0.1 vs control). At 15, 25 and 45 mg
FU kg-' b.w., '9F NMR spectra of perfusates showed small
signals of the classical catabolites of FU. 5,6-dihydro-5-
fluorouracil (FUH2, - 126.4 ppm) was only observed for 15
and 25 mg FU kg-' b.w. and when the perfusate was record-
ed at acidic pH (5.5) since FUH2 is unstable at basic pH
(Malet-Martino et al., 1986). The signal of FBAL was detect-
ed at -112.5 ppm when the perfusate was recorded at pH
5.5 and at -111.6 ppm when the perfusate was at pH> 7.5
since, at this pH, FBAL is present at N-carboxy-m-fluoro-p-
alanine (CFBAL) resulting from the reaction of FBAL with
HC03- in the perfusate (Martino et al., 1987). The signal of
FUPA (-111.3 ppm) and the resonance of the anabolite
5-fluorouridine (FUrd), one of the two FNUCs, were also
detected (Figure 2a). The only classical metabolite observed
for 90 or 180 mg FU kg' b.w. was FUrd. Moreover, FAC
was detected in all perfusates (Figure 2a). Its signal was
attributed by spiking with authentic standard. The addition
of authentic FAC led to an increase of the resonance at
- 141.4 ppm which appeared as a triplet (2JHF = 52.0 Hz) in
the '9F 'H-coupled spectra. The amount of FACin perfusates
increased with dose of FU (P <0.05 for all the doses vs all
the doses except for doses 15 mg kg-' vs 25 mg kg', 45 mg
kg- vs 90mgkg-' and 90mgkg-' vs 180 mgkg-) (Table
II). Several other signals (-113.8, -120.3, -121.4, -124.9,
- 126.2, - 158.4 ppm) corresponding to unknown com-
pounds were also observed in the '9F NMR spectra of per-
fusates from IPRH treated with FU (Figure 2a). The signals
of FAC, FNUCt, FNUCs, FBAL and the unknown reson-
ances were observed in the AS fractions of the PCA extracts
of hearts treated with 45 or 180 mg FU kg-' b.w. The signals
of 5-fluorouridine-2'-monophosphate and 5-fluorouridine-3'-
monophosphate were detected in the corresonding Al frac-
tions (Parisot et al., 1991). These observations indicate that
FU was only slightly metabolised by IPRH. For short life
times (60-70 min), the case of 90 and 180mg FU kg' b.w.
doses, only slight anabolism occurred. For longer life times
(>100 min), the case of 15, 25 and 45 mg FU kg-' b.w.
doses, some catabolism was also observed. On the other
hand, for all doses of FU, we observed significant amounts
of FAC. The cardiotoxic symptoms and the intramyocardial
accumulation of citrate were attributed to this compound.
Indeed, the time before ventricular arrest decreased when the
concentration of FAC in the perfusate increased (Table II).
Moreover, early ventricular arrest was noted and intra-
myocardial citrate levels rose markedly (P<0.0005 vs cont-
rol) after treatment of IPRH with FAC at 0.25 or 2 mg kg-'
b.w. (Table II).
Table II Data ofexperiments with isolated perfused rabbit hearts
Dose
mgkg-' b.w. Ventricular arrest Citrate FAC inperfusate Number of
Compound injected (;Lmole kg-' b.w.) min ,gg'- ofheart pmoles experiments
None 7+4 iia
FU (Tris) Roche 15 (115) 167±2b 188±41c 0.4±0.08d 3
25 (192) 118±13e 171±52c 0.5±0.2f 3
45 (346) 100±289 273±47c 1.4±0.3h 4
90 (692) 64±6' 152± 13c 1.7±0.2' 3
180 (1385) 70± 14 318± 135c 2.1 ±0.7 5
Tris 305 (2520) 70k 10±51 3
FAC sodium salt 0.25m (2.5) 62±13 278± 120C Injected 3
2 (20) 38±9 341 ± 75c Injected 3
FBAL hydrochloride 50 (348) 240n 19 10
200 (1394) 240n 8 10
FU Sigma 25 (192) 240n 8±31 4
180 (1385) 240n 11±4' 3
FU'purified' 180 (1385) 240n 14±8' 3
Facet-Tris (oxazolidine 2) 0.39P (2.35) 140± 15q 360 120C 2.4±0.4' 3
English FU (NaOH) Roche 180 (1385) 106± 35 142±59c 0.5±0.05r,s 3
German FU (NaOH) Roche 180 (1385) 240 , 139 305, 397 0.6, 0.4 2t
American FU (NaOH) Roche 180 (1385) 240n 65 33C 0.2 0.05r 3
American FU (NaOH) Solopak 180 (1385) 240-, 149, 190 209 I81c 0. ±0.O1r 3
Results are expressed as mean values±s.d. aThree sets ofcontrol experiments were carried out. The amount ofintramyocardial citrate was
measuredinisolatedheartswithoutperfusion(n = 5),inisolatedheartsperfusedwithablankperfusate,i.e.,withoutFU,during 1 h30(n = 4)or
during 4 h (n = 2). Since the values were similar, the mean of the 11 experiments was taken as the control value, bSignificant at P<0.025
compared with FU (Tris) at 25 or 45 mgkg-' b.w. and at P<0.0005 compared with FU (Tris) at 90 or 180 mg kg- I b.w., cSignificant at
P<0.0005 vscontrol hearts, dNot significantcompared with FU (Tris) at 25 mgkg-' b.w., significant at P<0.01 compared with FU (Tris) at
45, 90 or 180 mgkg-' b.w., 0Not significant compared with FU (Tris) at 45 mg kg-' b.w., significant at P<0.005 compared with FU (Tris) at
90 mg kg-' b.w., and at P<0.0005 compared with FU (Tris) at 180 mg kg-' b.w.,'Significant at P<0.005 compared with FU (Tris) at45, 90,
or 180mg kg-' b.w., "Not significant compared with FU (Tris) at 90mgkg-' b.w., significant at P<0.01 compared with FU (Tris) at
180 mg kg-' b.w., hNotsignificantcomparedwith FU(Tris) at90 mg kg-' b.w., significant at P<0.05comparedwithFU(Tris)at 180 mg kg-'
b.w.,'Notsignificantcomparedwith FU(Tris) at 180 mg kg-' b.w., Assumingthattheconcentration ofTris in aFU Rochevialis84.7 mg ml-'
(Matsubara et al., 1980), this dose ofTris is equivalent to that brought by a FU (Tris) Roche vial in an experiment at 180mg FU kg-' b.w.,
kIntentionally stopped at the mean time ofventricular arrest observed for adoseof 180 mg FU (Tris)kg-' b.w.,'Not significant compared with
control hearts, mThis dose ofFAC corresponds to the amount ofFacet-Tris (oxazolidine 2) injected when hearts were treated with FU (Tris)
Roche vials (batch B034S) at 180 mg FU kg-' b.w., The purity ofFAC sodium salt was 95%, 0Internationally stopped, 'Since FBAL is very
expensive and difficult to get, only one experiment was conducted with each dose, PThis dose corresponds to the amount of Facet-Tris
(oxazolidine2) injected when hearts were treated with FU (Tris) Roche vials (batch B034S) at 180mg FU kg-' b.w., qSignificant at P<0.0005
compared with FU (Tris) at 180 mgkg-' b.w., rSignificant at P< 0.005 compared with FU (Tris) at 180mgkg-' b.w., 2Significant at P< 0.01
comparedwithUSFU(NaOH) RocheorSolopak,'OnlytwoexperimentsweredonewiththeGerman FU(NaOH) Rochesincewecouldnotget
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Figure 2 'H-decoupled '9F NMR spectra of a, a perfusate from an isolated perfused rabbit heart treated with FU (Tris) Roche at
25 mg FU kg-' b.w. The pH was 7.93. The number of scans was 36775. b, a FU (Tris) Roche vial. The pH was 8.42. The number
of scans was 368.
What is the origin ofFAC?
We first surmised that it derived from the metabolic transfor-
mation of FBAL (Figure 1). However, there was no cardio-
toxicity and no marked rise in intramyocardial citrate after
treatment of IPRH with FBAL at 50 or 200mgkg-' b.w.
over 4 h (Table II). Only the signal of FBAL was found in
the AS fractions of heart PCA extracts, demonstrating its
effective uptake, and in the perfusates. No FAC was detect-
ed. These results show that, even in presence ofhigh amounts
of FBAL, this compound is not metabolised into FAC, at
least not in amounts that can be detected by '9F NMR.
We therefore concluded that FAC must be present in the
injected solution, i.e. in FU Roche vials. The '9F NMR
analysis of FU (Tris) Roche vials of various lots revealed,
besides FU itself, six fluorinated compounds accounting for
1.55 ± 0.35 mole% relative to FU (n = 7) (Table III, Figure
2b). Apart from the resonance at - 43.2 ppm corresponding
to fluoride ion, the other signals were unidentified. None of
them corresponded to FAC (- 141.0 ppm) or FC (-114.5
ppm, d, JHF = 50.7 Hz).
FAC found in the perfusates of IPRH must therefore have
come from transformation of impurity(ies) in the solution of
FU. To check that the formation of FAC was a metabolic
process rather than a chemical transformation taking place
during the perfusion, control experiments consisting in per-
Table III '9F NMR chemical shifts, multiplicity and proportions
of fluorinated impurities in FU (Tris) Roche vials of various
batchesa (n = 7)
abbc Multiplicity, coupling Proportion±s.d.
(ppm) constants J (Hz) (mole %)
-43.2 s 0.08±0.03
-117.2e dd, 48.5, 15.7 -f
-122.3 dd, 49.6, 18.4 0.52±0.08
- 124.8 dd, 48.9, 22.5 0.05±0.01
- 125.9 dd, 49.6, 20.6 0.57±0.16
- 159.7 td, 46.8, 18.9 0.32±0.13
aBatches analysed: B034S, B035S, B044T, B045T, B048T,
B049T, B051T, bChemical shifts are related to external
trifluoroacetic acid, cThe pH of the vials was 8.45+0.16, dS = s_
inglet, d = doublet, t = triplet, eOnly detected in four out of seven
vials analysed, fToo low to be accurately quantified.
fusates containing FU from FU Roche vials and circulating
during 2 or 4 h in the perfusion system without heart were
carried out. The resonance of FU and those at - 119.6,
- 121.3, -124.6, -126.0, -158.3 ppm were the only signals
found in the '9F NMR spectra of such perfusates. This also
accounts for the unknown resonances observed in the spectra
a
FAC
FUrd
FU
I~~~~rf
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of heart perfusates. FAC was not detected. FAC was there-
fore assumed to be formed via a metabolic process.
Various other experiments were conducted to verify that
impurity(ies) was(were) the precursor of FAC and the caus-
ative factor of FU cardiotoxicity. No cardiotoxic symptoms
were observed during the 4 h of perfusion of IPRH treated
with FU Sigma at 25 or 180 mg kg-' b.w., a powder that we
dissolved in Tris buffer and that contained no fluorinated
impurities (Table II). Furthermore, there was no elevation in
citrate levels with respect to the control (P>0.1). For both
doses, small signals of FUrd, FUPA, FBAL, FUH2 were
observed in the '9F NMR spectra of the perfusates. The
signal of FAC was undetected. At 180mg FU kg-' b.w., we
also observed a signal at - 133.3 ppm corresponding to an
unknown metabolite.
When vials of FU (Tris) Roche were treated in acidic
conditions, FU precipitated and the '9F NMR spectrum of
the powder after its redissolution in Tris buffer showed no
fluorinated impurity. IPRH were treated with this 'purified'
solution at 180 mg FU kg-' b.w. No symptoms of cardiotox-
icity appeared during the 4 h of perfusion. There was no
significant intramyocardial accumulation of citrate (P>0.05
vs control) and FAC was not detected in the perfusates
(Table II).
The fact that the cardiotoxicity was due to impurity(ies) in
FU Roche vials was confirmed by a last experiment with a
sample of FU powder that Hoffmann-La Roche sent us and
that we dissolved in Tris buffer immediately before the
experiment. No fluorinated impurities were observed in the
'9F NMR spectrum of this solution. There was no evidence
of cardiotoxicity, nor any rise in intramyocardial citrate (4 yg
g-I of heart) and no detectable FAC in perfusates after
treatment of IPRH with this solution at 180 mg FU kg-'
b.w.
Therefore, FAC must have come from the metabolic trans-
formation of degradation compound(s) contained in vials of
FU Roche that is(are) formed during the storage of the
solution.
Identification ofthe precursor ofFAC in FU (Tris) Roche
vials
We noticed that the intensity of the signal at - 159.7 ppm
relative to those of the signals at - 122.3 and - 125.9 ppm
was higher in the '9F NMR spectra of FU (Tris) Roche vials
than in those ofperfusates ofIPRH (compare Figures 2a and
2b). FAC was therefore assumed to be derived essentially
from the metabolic conversion of the compound resonating
at - 159.7 ppm.
The simplest hypothesis was that FAC resulted from meta-
bolic oxidation of Facet. We thus synthesised this compound
by oxidation of fluoroethanol. In H20, it exists as the alde-
hyde hydrate 1. It reacts with Tris to give a compound
(Facet-Tris) whose structure was determined as the oxazoli-
dine 2, which on acid hydrolysis gives Facet hydrate 1 in the
following reaction:
The compound resonating at - 159.7 ppm was extracted
from vials of FU (Tris) Roche. It had identical spectroscopic
characteristics to those of the oxazolidine 2.
When IPRH were treated with this compound at an equiv-
alent dose to that that would have been injected if hearts
were treated with FU Roche vials at 180 mgkg-' b.w., vent-
ricular arrest occurred at 140 ± 15 min, citrate levels rose
significantly (P<0.0005 vs control) and FAC was the main
compound detected in the '9F NMR spectra of perfusates in
a similar amount to that found in perfusates of hearts treated
with FU (Tris) Roche vials at 180mgkg-' b.w. (P>0.1)
(Table II). The other small signals were unmetabolised oxa-
zolidine 2 and Facet hydrate 1.
Therefore, a depot form of Facet that is converted into
FAC by isolated perfused hearts is present in vials of FU
(Tris) Roche.
'9FNMR analysis ofurinefrom patients treated with FU
(Tris) Roche vials
Thirty-three urine samples from 15 patients (six with cardio-
toxic symptoms, nine without) treated with continuous i.v.
infusion of FU (Tris) Roche were analysed. Unmetabolised
FU and its classical catabolites (FUH2, FUPA, FBAL and its
derivatives, F-) were observed in the '9F NMR spectra. In
addition, FAC was detected in all urine samples analysed
irrespective of any reported cardiotoxicity. In some samples,
it was also possible to detect the signals in the - 120 ppm
area found in FU vials. The signal of the oxazolidine 2 was
not observed. A low signal of Facet hydrate was detected in
some samples. A resonance with a 6 varying between - 153.0
and - 154.5 ppm and attributed to a compound resulting
from the chemical interaction of Facet with an unknown
urinary component was observed in most samples. The quan-
titative analysis of urine samples from six patients showed
that the ratio FAC excreted in 24 h/FU catabolites excreted
in 24 h increased during the treatment for five patients
(Figure 3).
* Day 1
* Day 2
,, X 20 30 Day3
o - 1B Day4 .ox
co.
) C4J 10a
IL.
'-0
Patient 1 Patient 2 Patient 3 Patient4 Patient5 Patient6
Figure 3 Ratios of FAC excreted over 24 h/FU catabolites exc-
reted over 24 h in urine samples from six patients treated with a
continuous i.v. infusion of FU (0.6 to 1 g/m2/day) over 4 con-
secutive days. 'No sample available.
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FAC was not detected in the three plasma samples analys-
ed. This could be explained by the relative insensitivity of
NMR (detection threshold with our spectrometer 3-5 g.M).
FU (NaOH) vials
To our knowledge, FU dissolved in Tris is used in France
and Japan. In other countries (Germany, Great Britain,
USA ...), FU vials contain FU dissolved in a sodium hydrox-
ide solution. It was therefore interesting to analyse this kind
of vials and to study their effect on IPRH. We analysed vials
of FU manufactured by Roche in Great Britain, Germany or
USA, as well as a US generic. All these vials gave similar 19F
NMR spectra (Figure 4b). The spectra were, however, more
complex than those of the FU (Tris) vials (compare Figures
2b and 4b). F- was the main impurity (representingt0.3-
1.5 mole% relative to FU) but signals from approximately 50
different fluorinated substances could be observed at individ-
ual concentrations of approximately 0.005-0.1 mole%. The
FU
total of the combined fluorinated impurities came to between
1 and 3 mole%. Since these vials do not contain Tris, any
Facet present should be in the form of the hydrate 1 and not
the oxazolidine 2. We therefore sought Facet hydrate. There
was a marked increase in the signal at - 155.16 ppm after
spiking the sample with Facet hydrate, although more detail-
ed examination of this signal (which represents %0.0I-0.05
mole%) showed two close signals (Au;)3 Hz), one of which
was Facet hydrate (Figure 4b insert). This impurity could not
therefore be quantified accurately.
IPRH were treated with the content of these vials at
180 mg FU kg-' b.w. Ventricular arrest occurred at various
times even in experiments with vials of the same origin
(Table II). However, we consistently observed episodes of
arrythmia after around 2 h. The German FU led to a marked
rise in intramyocardial citrate, comparable to that observed
with FU (Tris) Roche. There was a lower but significant rise
in citrate levels after treatment with the contents of the
American and English FU vials (P<0.0005 vs control). FAC
a
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Figure 4 'H-decoupled '9F NMR spectra of a, a perfusate from an isolated perfused rabbit heart treated with FU (NaOH) Roche
manufactured in Germany at a dose of 180 mg FU kg-' b.w. The pH was 7.38. The number of scans was 46313. b, a vial of FU
(NaOH) Roche manufactured in Germany. The pH was 8.5. The number of scans was 35324.
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was detected in all perfusates analysed irrespective of the
origin of the injected vial (Figure 4a), but in a significantly
lower amount than that observed in perfusates of hearts
treated with FU (Tris) at the same dose (P<0.005 for
American and English FU vials vs FU (Tris) vials). However,
the amount of FAC was higher in the perfusates of hearts
treated with German and English FU than in those of hearts
treated with US FU (P<0.01 for English FU vs US FU).
Discussion
The original aim of this study was to relate the cardiotoxicity
of FU to metabolism of the drug in the heart. Indeed,
Japanese workers had reported that the ECG changes elicited
by i.v. administration of FU to the guinea pig were assoc-
iated with an intracellular depletion ofhigh-energy phosphate
compounds and a substantial elevation of intramyocardial
citrate level (Matsubara et al., 1980). They suggested that the
accumulation of citrate was due to the formation of FAC
from FU via FBAL. Formation of FAC from FBAL has
also been proposed as a biochemical basis for FU-related
neurotoxicity (Philips et al., 1959; Koenig & Patel, 1970).
However, attempts to demonstrate the presence of FAC in
acid-soluble extracts of mouse liver and kidney and in the
urine of mice, cats or humans given FU have so far been
unsuccesful (Mukherjee & Heidelberger, 1960; Hull et al.,
1988). Also, no metabolism of [2-'4C]FBAL into FAC has
been observed in mice and cats (Mukherjee & Heidelberger,
1960). So, the detection of FAC in perfusates of isolated
rabbit hearts treated with FU vials (Figures 2a and 4a) was
surprising, especially as significant amounts of FAC, but not
of the usual metabolites of FU, were detected in the experi-
ments with FU (Tris) Roche at 180 mgkg-' b.w. Moreover,
since FBAL was not converted into FAC by isolated heart,
the significant amounts of FAC observed in our experiments
could not have come from metabolism of FU via FBAL.
The lack of symptoms ofcardiotoxicity and the absence of
FAC in perfusates of hearts treated with FU powder (Sigma,
Roche) dissolved just before use suggested that the origin of
FAC had to be searched in the injected vials. FU vials
contain fluorinated impurities whether NaOH or Tris solu-
tions are used to dissolve the drug (Figures 2b and 4b).
Fluoride ion was found in both types of vial. A critical
impurity was identified in the FU Tris vials, namely the
oxazolidine of Facet. It is known that Tris reacts readily with
propionaldehyde or aldoifosfamide to produce the corre-
sponding oxazolidines (Borch & Getman, 1984; Zon et al.,
1984). We demonstrated by synthesis and isolation of this
impurity and with conventional spectroscopic techniques that
Tris also reacts with Facet to give the fluorinated oxazolidine
2. Injected into IPRH, it is metabolised into Facet and FAC.
Thus, a depot form of Facet is present in FU (Tris) vials. It
was noteworthy, however, that the ventricular arrest induced
by the FU (Tris) Roche vials injected into IPRH at a dose of
180 mg FU kg-' b.w. occurred significantly earlier (P<
0.0005) than that induced by the oxazolidine 2 injected alone
at a dose equivalent to that injected with FU Tris vials for a
dose of 180mg FUkg-' b.w. (70 and 140 min respectively).
Since a freshly made up solution of FU did not induce
symptoms of cardiotoxicity under our experimental condi-
tions, it is likely that the impurities giving signals at
- 122.3 and - 125.9 ppm have some responsibility for the
toxicity although probably not via FAC since the amount of
FAC detected did not differ significantly between hearts
treated with FU (Tris) vials at 180 mgkg' b.w. and those
treated with oxazolidine 2 at a dose equivalent to that
injected with FU Tris vials for a dose of 180 mg FU kg-'
b.w. In FU NaOH vials, we could identify Facet, and many
unidentified fluorinated impurities were also detected.
These impurities are degradation products of FU, which
form during storage in basic medium. To our knowledge,
there are no detailed reports of the stability of FU or of
identification of its products of decomposition. However, it
has been reported that FU degrades more rapidly in alkaline
than in weakly acidic conditions (Garrett et al., 1968;
Tomankova & Zyka, 1977). In preliminary experiments, we
examined the stability of FU at a concentration of 50mg
ml-' in Tris solution (1 M) at pH 8.5 and 25°C (data not
shown). The signals at - 122.3 and - 125.9 ppm were detect-
ed within 4 days after dissolving FU powder in Tris; by day
14, we also observed the signals of fluoride ion and the
compounds resonating at -117.2 and - 124.8 ppm, and by
day 20, the signal ofthe oxazolidine 2. A more detailed study
of the mechanism of the alkaline hydrolysis of FU is in
progress. The decomposition of FU in alkaline medium
which is required for solubilisation leads to a compound that
is metabolised to highly toxic FAC (LD 50 = 0.1-7.5 mg
kg-' b.w. depending on the species (Meldrum & Bignell,
1957)). FAC exerts specific actions on the myocardium and
nervous system causing ventricular fibrillation and/or convul-
sions (Chenoweth & Gilman. 1946). To avoid any possibility
of chemical degradation, the solution of FU should be pre-
pared immediately before injection. Modification of the
manufacturing procedure for FU vials (a lyophilised form for
example) should help limit the cardiotoxicity (and maybe
also the neurotoxicity) of this drug.
FAC was consistently detected in the urine of patients
treated with high doses of FU Tris Roche, the only formula-
tion and brand available in France. There appeared to be no
relationship, however, between urinary levels and clinical
cardiotoxic symptoms. Various factors could account for
this. Variations in the amounts of FAC, either from differ-
ences in amounts of Facet injected depending on the injected
batch, or from individual differences in metabolising Facet or
in defluorinating FAC, the main metabolic pathway of FAC
detoxification (Mead et al., 1979; Tecle & Casida, 1989), the
existence of underlying myocardial disease could account for
the incidence of ;10% reported for FU-related cardiotox-
icity in most clinical studies. We noticed an increase in the
daily urinary excretion of FAC during perfusion of FU in
five out of the six patients studied (Figure 3). This could
account for one of the striking features of FU cardiotoxicity
namely the delayed onset with respect to the beginning of the
treatment of clinical cardiotoxic symptoms (Collins &
Weiden, 1987; Freeman & Costanza, 1988; de Forni et al.,
1990; 1991).
Although our results are preliminary, we did observe
differences in cardiotoxic effects and citrate levels between the
German, English and American FU NaOH vials (Table II).
Since the '9F NMR spectra from these formulations are
similar but very complex, we cannot readily account for these
diverse data. Work is in progress to elucidate the matter.
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